Lead Product(s): Set-point vaccines
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Vickers Venture Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 09, 2020
The financing will support a first-in-man Phase I clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase Ib clinical trials in the endemic regions of Singapore and Brazil.